A New Type of Congenital Dysfibrinogen, Fibrinogen Bremen, with an Aα Gly-17 to Val Substitution Associated with Hemorrhagic Diathesis and Delayed Wound Healing
Yasuo Wada
1
The Division of Hemostasis and Thrombosis Research, Institute of Hematology, Tochigi, Japan
,
Kazuki Niwa
1
The Division of Hemostasis and Thrombosis Research, Institute of Hematology, Tochigi, Japan
,
Hisato Meakawa
1
The Division of Hemostasis and Thrombosis Research, Institute of Hematology, Tochigi, Japan
,
Shinji Asakura
1
The Division of Hemostasis and Thrombosis Research, Institute of Hematology, Tochigi, Japan
,
Teruko Sugo
1
The Division of Hemostasis and Thrombosis Research, Institute of Hematology, Tochigi, Japan
,
Makoto Nakanishi
2
The Department of Biochemistry, Jichi Medical School, Tochigi, Japan
We have identified a new type of Aα Gly-17 to Val substitution in a congenital dysfibrinogen, fibrinogen Bremen, derived from a 15-year-old boy having manifested easy bruising and delayed wound healing. The functional abnormality was characterized by altered fibrin monomer polymerization, which became evident by increasing the salt concentration and pH. A synthetic tetrapeptide with a sequence of the amino-terminal segment of normal fibrin α-chain, Gly-Pro-Arg-Val, substantially inhibited polymerization of both normal and the patient-derived fibrin monomers. A synthetic tetrapeptide with the Bremen type sequence of Val-Pro-Arg-Val inhibited polymerization of the patient’s fibrin monomers partially at a peptide: fibrin monomer molar ratio of 4,000:1, and that of normal one at a much higher ratio of 10,000:1. Likewise, a synthetic peptide Ala-Pro-Arg-Val with a replacement of the Gly residue by another aliphatic amino acid Ala inhibited similarly the patient’s fibrin monomer polymerization. Thus, the hypothetical two-pronged socket-like structure consisting of the α-amino group of the amino-terminal Gly and the guanidino group of an Arg at position 3 of the normal fibrin α-chain seems to be restored considerably in the mutant fibrin α-chain at low ionic strengths and pH’s, despite the replacement of the amino-terminal Gly by another aliphatic amino acid Val.
References
1
Doolittle RF.
Structural aspects of the fibrinogen-fibrin conversion. Adv Prot Chem 1973; 27: 1-109
9
Olexa SA,
Budzynski AZ.
Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980; 77: 1374-1378
11
Southan C,
Thompson E,
Panico M,
Etienne T,
Morris HR,
Lane DA.
Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen. J Biol Chem 1985; 260: 13095-13101
12
Váradi A,
Scharaga HA.
Localization of segments essential for polymerization and for calcium binding in the γ-chain of human fibrinogen. Biochemistry 1986; 25: 519-528
13
Ugarova T,
Budzynski AZ.
Interaction between complementary polymerization sites in the structural D and E domains of human fibrin. J Biol Chem 1992; 267: 13687-13693
14
Laudano AP,
Doolittle RF.
Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci USA 1978; 75: 3085-3089
15
Laudano AP,
Doolittle RF.
Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry 1980; 19: 1013-1019
16
Shimizu A,
Saito Y,
Matsushima A,
Inada Y.
Identification of an essential histidine residue for fibrin polymerization. Essential role of histidine 16 of the Bβ-chain. J Biol Chem 1983; 258: 7915-7917
18
Yamazumi K,
Doolittle RF.
Photoaffinity labeling of the primary fibrin polymerization site: Localization of the label to γ-chain Tyr-363. Proc Natl Acad Sci USA 1992; 89: 2893-2896
20
Southan C.
Molecular and genetic abnormalities of fibrinogen. In: Fibrinogen, Fibrin Stabilisation, and Fibrinolysis.
Francis JL.
(ed)
Ellis Horwood, Chichester. 1988. pp 65-99
25
Matsuda M,
Baba M,
Morimoto K,
Nakamikawa C.
An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. J Clin Invest 1983; 72: 1034-1041
26
Yamazumi K,
Shimura K,
Terukina S,
Takahashi N,
Matsuda M.
A γ methionine-310 to threonine substitution and consequent N-glycosylation at γ asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi. J Clin Invest 1988; 83: 1590-1597
29
Lundblad RL.
A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme with phenylmethylsulfonyl fluoride. Biochemistry 1971; 10: 2501-2506
30
Marder VJ,
Shulman NR,
Carroll WF.
High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physiochemical and immunological characterization. J Biol Chem 1969; 244: 2111-2119
31
Gollwitzer R,
Timpl R,
Becker U,
Furthmyer H.
Chemical and immunological properties of reduced and alkylated polypeptide chains of bovine fibrinogen. Eur J Biochem 1972; 28: 497-506
34
Asakura S,
Hirata H,
Okazaki H,
Hashimoto-Gotoh T,
Matsuda M.
Hydrophobie residues 382-386 of antithrombin III, Ala-Ala-Ala-Ser-Thr, serve as the epitope for an antibody which facilitates hydrolysis of the inhibitor by thrombin. J Biol Chem 1990; 265: 5135-5138
36
Terukina S,
Matsuda M,
Hirata H,
Takeda Y,
Miyata T,
Takao T,
Shimonishi Y.
Substitution of γ Arg-275 by Cys in an abnormal fibrinogen, “fibrinogen Osaka II”: evidence for a unique solitary cystine structure at the mutation site. J Biol Chem 1988; 263: 13579-13587
37
Maekawa H,
Yamazumi K,
Muramatsu S,
Kaneko M,
Hirata H,
Takahashi N,
de Bosch NB,
Carvajal Z,
Ojeda A,
Arocha-Pinango CL,
Matsuda M.
An Aα Ser-434 to N-glycosylated Asn substitution in a dysfibrinogen, fibrinogen Caracas II, characterized by impaired fibrin gel formation. J Biol Chem 1991; 266: 11575-11581
39
Kehl M,
Lottspeich F,
Henschen A.
Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe-Seyler 's Z Physiol Chem 1981; 362: 1661-1664
41
Maekawa H,
Yamazumi K,
Muramatsu S,
Kaneko M,
Hirata H,
Takahashi N,
Arocha-Pinango CL,
Rodriguez S,
Nagy H,
Perez-Requejo JL,
Matsuda M.
Fibrinogen Lima: a homozygous dysfibrinogen with an Aα-arginine-141 to serine substitution associated with extra N-glycosylation at Aα-asparagine-139. J Clin Invest 1992; 90: 67-76
42
Miyata T,
Terukina S,
Matsuda M,
Kasamatsu A,
Takeda Y,
Murakami T,
Iwanaga S.
Fibrinogens Kawaguchi and Osaka: an amino acid substitution of Aα-arginine-16 to cysteine which forms an extra interchain disulfide bridge between the two Aα chains. J Biochem 1987; 102: 93-101
44
Blombäck B,
Blomb ck,
Hessel B,
Iwanaga S.
Structure of N-terminal fragments of fibrinogen and specificity of thrombin. Nature (Lond) 1967; 215: 1445-1448
45
Blombäck M,
Blombäck B,
Mammen EF,
Prasad AS.
Fibrinogen ‘Detroit’: a molecular defect in the N-terminal disulphide knot of human fibrinogen. Nature (Lond) 1968; 218: 134-137
46
Henschen A,
Kehl M,
Southan C,
Lottspeich F,
Georgopoulos D.
Genetically abnormal fibrinogens - some current characterisation strategies. In: Fibrinogen - Structure, Functional Aspects, Metabolism.
Haverkate F,
Henschen A,
Nieuwenhuizen W,
Straub PW.
(eds)
Walter de Gruyter. Berlin: 1983. pp 125-144
47
Dempfle CEH,
Henschen A.
Fibrinogen Mannheim I - Identification of an Aα 19 Arg-Gly substitution in dysfibrinogenaemia associated with bleeding tendency. In: Fibrinogen 4. Current Basic and Clinical Aspects.
Matsuda M,
Iwanaga S,
Takada A,
Henschen A.
(eds)
Else vier, Amsterdam: 1990. pp 159-166
48
Blombäck B,
Hessel B,
Field R,
Procyk R.
Fibrinogen Aarhus: An abnormal fibrinogen with Aα 19 Arg Gly substitution. In: Fibrinogen 3. Biochemistry, Biological Functions, Gene Regulation and Expression.
Mosesson MWE,
Amrani DL,
Siebenlist KR,
DiOrio JP.
(eds)
Elsevier, Amsterdam: 1988. pp 263-266
49
Yoshida N,
Okuma M,
Hirata H,
Matsuda M,
Yamazumi K,
Asakura S.
Fibrinogen Kyoto II, a new congenitally abnormal molecule, characterized by the replacement of Aα proline-18 by leucine. Blood 1991; 78: 149-153
50
Uotani C,
Miyata T,
Kumabashiri I,
Asakura H,
Saito M,
Matsuda T,
Kajiyama S,
Iwanaga S.
Fibrinogen Kanazawa: a congenital dysfibrinogenemia with delayed polymerization having a replacement of proline-18 by leucine in the Aα chain. Blood Coagulation and Fibrinolysis 1991; 2: 413-417
51
Cochrane CG,
Revak SD,
Wuepper KD.
Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med 1973; 138: 1564-1583